Merck , the rival of Sanofi-Aventis who are the developer of Taranabant are doing a two year study .The study has reached in its final month of the total time with 2,400 paticipants.
The approval of diet drug taranabant to the market in the
There is no significance of interim results of the trial to scientific meetings.
The expectation of approval of pill for weight loss, rimonabant ended as FDA continuously delayed action and sanofi finally dropped its application in June. The FDA advisory did not recommend the diet drug in the market of
Taranabant is passing through the clinical process quietly which began many years behind rimonabant. In fall 2005 the participants were enrolled for the phase -3 trials which will be completed in the early 2008.
It is expected to come the final result of this trial until spring in which the participants were rerandomized for the second year to find out dose to keep off weight lost in the first.
The interim trial results may be provided by the Merck may bring in notice that it is more exciting diet aid than rimonabant.
1 comment:
Post a Comment